I
didn’t attend this summit, but wish I did.
To make up for it, I watched the keynote address
from Dr. Webster Cavenee, “…a world renowned researcher and long standing,
trusted advisor, from Ludwig Institute for Cancer Research and the University
of California San Diego.” According to the NBTS website he delivered “…a keynote presentation describing our most
innovative strategic research initiative to date, our Defeat GBM Research
Collaborative, and the potential for a future global model of integrated brain
cancer research.”
His presentation is informative, straight-forward and pretty blunt about the complexity
and difficulty of the task at hand. Here’s a link: http://www.braintumor.org/about-us/nbts-summit/
On
the same web page is a link to the presentation by Michael Nathanson, Chairman
of the NBTS Board of Directors, about work being done by the National Brain
Tumor Society, in which he discussed:
“Our
Clinical Trial Endpoints Initiative – a program with the support of the U.S.
Food and Drug Administration (FDA) aimed at increasing the volume and speed of
approvals for new treatment;
Advancing Research to Therapies (ART) for
Brain Tumors – a new program aiming to translate laboratory science into
commercialized treatments by bringing together researchers, biotech and pharma
executives, investors, and patients;
Advocating for Oral Chemotherapy Parity
legislation protecting patients from paying out-of-pocket for life-saving
treatments just because they are prescribed in pill form; and much more.”
Lastly,
the site also provides a link to Summit’s “The State of Research Breakfast”
presentation in which experts in the field and National Brain Tumor Society
leadership briefed the audience on the “current state of pediatric brain tumor
research and the future of our work.”
No comments:
Post a Comment